Author:
Novković Mira,Knežević Violeta
Abstract
Introduction: End-stage renal disease is a terminal illness with a glomerular filtration rate of less than 15 mL/min. when must start one of the methods of renal replacement therapy: hemodialysis, peritoneal dialysis or kidney transplantation. Peritoneal dialysis is based on the processes of diffusion and osmosis, while the transport of substances takes place through the peritoneal membrane. The advantages of peritoneal dialysis compared to hemodialysis include longer-term preservation of residual renal function, preservation of blood vessels and a better quality of life for the patient. Complications of peritoneal dialysis can be infectious, metabolic and mechanical. Encapsulating peritoneal sclerosis (EPS) is a life-threatening complication of peritoneal dialysis (PD) treatment. The incidence of EPS is variable between 0.7 and 3.7%, while it increases with the length of PD treatment (0.7-6.4% after 5 years to as much as 17.2% after 15 years). The diagnosis of EPS is based on clinical symptoms. and signs as well as specific, but not pathognomonic, radiological and pathohistological findings. Features of IPS on computed tomography (CT) images are thickening and calcification of the peritoneal membrane, thickening of the intestinal wall, narrowing and dilatation of the in-testine, as well as "trapped" fluid collections. Case report: A 60-year-old patient, who has been treated with peritoneal dialysis for 4 years, was hospitalized due to severe gastrointestinal complaints. Due to clinical findings a peritoneal equilibration test was performed, which determined that it was a moderately fast transporter. Based on the findings of the computed tomography, the diagnosis was confirmed. Treatment is started tamoxifen and prednisone was started, the response to therapy was positive. Despite the control of sclerosing peritonitis, death occurred because of cardiac decompensation. Conclusion: Early diagnosis is necessary to start specific treatment in a timely manner and, if possible, preserve peritoneal dialysis as a treatment method and patient survival.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference10 articles.
1. Bargman JM, Skorecki K. Chronic Kidney Disease. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison's principles of internal medicine. 19th ed. New York: The McGraw-Hill Companies, Inc.; 2015. p. 1811-21;
2. Baralić M. Strukturne i funkcionalne promene fibrinogena kod bolesnika na pritoneumskoj dijalizi (doktorska disertacija). Beograd: Medicinski fakultet; 2022;
3. Cruz Andreoli M, Totoli C. Peritoneal Dialysis. Rev Assoc Med Bras (1992) 2020; 66 (SUPPL 1): S: 37-44;
4. Jagirdar R, Bozikas A, Zarogiannis S, Bartosova M, Schmitt C, and LiakopoulosV. Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options. International Journal of Molecular Sciences 2019 Nov 16;20(22):5765;
5. Zvizdic Z, Summers A, Moinuddin Z, Van Dellen D, Pasic-Sevic I, Skenderi F, et al. A Successful Treatment of Encapsulating Peritoneal Sclerosis in an Adolescent Boy on Long-term Peritoneal Dialysis: A Case Report. Prague Med Rep 2020;121(4):254-261;